Role of contrast-enhanced ultrasound in evaluating the efficiency of ultrasound guided percutaneous microwave ablation in patients with renal cell carcinoma
Abstract
Abstract
Objective: To evaluate the efficiency and feasibility of contrast-enhanced ultrasound (CEUS) in assessing of renal cell carcinomas (RCCs) following US-guided percutaneous microwave ablation (MWA).
Materials and Methods The CEUS results of the third day after ablation were compared with biopsy results and contrast-enhanced CT/MRI results simultaneously. The follow-up was administrated by CEUS and CT/MRI at 1, 3, 6 months and every 6 months subsequently. Combination of the clinical follow-up results and CT/MRI imaging results were reference standard of CEUS results for the long-term therapeutic effect.
Results: Eighty-three lesions with diameter 3.2±1.6cm (rang 0.6-7.8cm) were ablated. On the third day after MWA, CEUS showed 68 of 83 (81.9%) were successfully ablated and confirmed by 72 hours contrast-enhanced CT/MRI after MWA. Fifteen of 83(18.1%) appeared residual tumor on CEUS, then were performed biopsy and CEUS-guided ablation. Among 15 patients, 13 (86.7%) were verified with residual tumor by biopsy results. The sensitivity, specificity, accuracy, positive and negative predictive value were 100%, 97.1%, 97.6%, 86.7% and 100%, respectively. Seventy-six patients survived in the follow-up ranged from 3 to 74 (median 26) months. During the follow-up, the CEUS showed local recurrence in 7 patients, and six of them achieved consistent results on CEUS and CT/MRI imaging. The sensitivity, specificity, accuracy, positive and negative predictive value for detecting recurrence tumor were 85.7%, 98.7%, 97.6%, 85.7% and 98.7%, respectively.
Conclusion The post-procedural CEUS was demonstrated an efficient and feasible method in evaluating therapeutic effect of RCCs following MWA.
Downloads
Published
How to Cite
Issue
Section
License
License to Publish
Please read the terms of this agreement, print, initial page 1, sign page 3, scan and send the document as one file attached to an e-mail to gsersa@onko-i.si